Key factors in the research and development of new drugs for nonalcoholic steatohepatitis
DOI:10.3969/j.issn.1001-5256.2021.06.004
- VernacularTitle:非酒精性脂肪性肝炎新药研发的一些关键因素
- Author:
Zhaoyang GUO
1
;
Fajuan RUI
;
Jie LI
Author Information
1. Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
- Publication Type:Research Article
- Keywords:
Non-alcoholic Fatty Liver Disease;
Drug Discovery;
Models, Biological
- From:
Journal of Clinical Hepatology
2021;37(6):1254-1258
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) has become the most important chronic liver disease in China and a major cause of liver transplantation in developed countries in Europe and America. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to end-stage liver disease including liver cirrhosis and liver cancer, resulting in an increase in liver-related mortality. However, there are still no therapeutic drugs for NASH at present, and many new drugs are under development in ongoing clinical trials. The research and development of new drugs for NASH require the selection of an appropriate target population and treatment outcomes depending on anti-metabolic, anti-inflammatory or anti-fibrotic effect. This article summarizes and reviews several key factors in the research and development of new drugs for NASH.
